Pharmacological prevention of noise induced hearing loss

噪音性听力损失的药物预防

• 批准号: 407474878
• 负责人: Privatdozentin Dr. Verena Scheper
• 金额: --
• 依托单位: Hals-Nasen-Ohrenklinik
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2018
• 资助国家: 德国
• 起止时间: 2017-12-31 至 2021-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/407474878?language=en
• 关键词: Pharmacological; prevention; noise; induced; hearing

In Germany, 19 % of the population aged older than 14 years are hearing impaired. Noise is said to be the main reason for avoidable acquired hearing loss. To date, conservative methods such as hearing protection have been used to prevent hearing impairment. No preventive pharmacological therapies are available. In this study, active substances are identified for the preventive treatment of noise induced temporary (TTS) and permanent (PTS) threshold shift. As the stress on the inner ear repeatedly recurs within the course of life, and the traumas accumulate over time, a long-term application of the active substances is mandatory. An innovative way to release active ingredients over an extended period of time in the inner ear is cell-based therapy. Cells can genetically be modified to overexpress growth factor proteins. In the present study the basis for this innovative therapy strategy is investigated. The selected growth factors glial cell line-derived neurotrophic factor, erythropoietin and insulin-like growth factor-1 are examined for their potential to protect the hearing from noise trauma. In corresponding animal models, the acoustic thresholds before and after trauma exposure are examined and compared with those of non-treated animals.

在德国，14 岁以上人口中有 19% 患有听力障碍。据说噪音是可避免的获得性听力损失的主要原因。迄今为止，已使用听力保护等保守方法来预防听力障碍。没有可用的预防性药物疗法。在这项研究中，确定了用于预防性治疗噪声引起的暂时性（TTS）和永久性（PTS）阈值漂移的活性物质。由于内耳的压力在生命过程中反复出现，并且创伤随着时间的推移而累积，因此必须长期使用活性物质。细胞疗法是一种在内耳中长时间释放活性成分的创新方法。可以对细胞进行基因改造以过度表达生长因子蛋白。在本研究中，研究了这种创新治疗策略的基础。所选生长因子包括神经胶质细胞系衍生的神经营养因子、促红细胞生成素和胰岛素样生长因子-1，并检查其保护听力免受噪声损伤的潜力。在相应的动物模型中，检查创伤暴露前后的声阈值，并与未治疗动物的声阈值进行比较。